Article
Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-alpha-treated chronic myelogenous leukaemia patients.
Cancer immunology, immunotherapy : CII - 1 Jan 1990
Pawelec G, Ehninger G, Schmidt H, Müller C, Bühring H J, Reutter M, Busch F W
Abstract excerpt
Chronic myelogenous leukemia (CML) patients in chronic phase display compromised lymphokine-activated killer (LAK) cell induction, which is partly restored after therapy with interferon alpha. However, the relative resistance of the leukemic cells from these patients to autologous or allogeneic L...
Topics
- Antigens, Surface
- Cell Division
- Cell Survival
- Cytokines
- Cytotoxicity, Immunologic
- Humans
- Interferon Type I
- Interleukin-3
- Killer Cells, Lymphokine-Activated
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Phenotype
- Tumor Cells, Cultured